221 related articles for article (PubMed ID: 35034621)
1. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
Sharp J; Prasad V
BMC Cancer; 2022 Jan; 22(1):70. PubMed ID: 35034621
[TBL] [Abstract][Full Text] [Related]
2. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
5. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
Kurzrock R; Gurski LA; Carlson RW; Ettinger DS; Horwitz SM; Kumar SK; Million L; von Mehren M; Benson AB
Ann Oncol; 2019 Oct; 30(10):1647-1652. PubMed ID: 31373348
[TBL] [Abstract][Full Text] [Related]
6. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
Cliff ERS; Rome RS; Kesselheim AS; Rome BN
JAMA Netw Open; 2023 Nov; 6(11):e2343285. PubMed ID: 37962889
[TBL] [Abstract][Full Text] [Related]
7. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.
Unger JM; Nghiem VT; Hershman DL; Vaidya R; LeBlanc M; Blanke CD
JAMA Netw Open; 2019 Sep; 2(9):e1910593. PubMed ID: 31483471
[TBL] [Abstract][Full Text] [Related]
8. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
10. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
Mooghali M; Mitchell AP; Skydel JJ; Ross JS; Wallach JD; Ramachandran R
BMJ Med; 2024; 3(1):e000802. PubMed ID: 38596814
[TBL] [Abstract][Full Text] [Related]
11. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
12. First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.
Zornosa C; Vandergrift JL; Kalemkerian GP; Ettinger DS; Rabin MS; Reid M; Otterson GA; Koczywas M; D'Amico TA; Niland JC; Mamet R; Pisters KM
J Natl Compr Canc Netw; 2012 Jul; 10(7):847-56. PubMed ID: 22773800
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
[TBL] [Abstract][Full Text] [Related]
14. Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.
Zimmerman KO; Smith PB; McMahon AW; Temeck J; Avant D; Murphy D; McCune S
JAMA Pediatr; 2019 Jan; 173(1):60-67. PubMed ID: 30452504
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
[TBL] [Abstract][Full Text] [Related]
16. US Food and Drug Administration regulatory updates in neuro-oncology.
Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
19. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.
Carlisle BG; Doussau A; Kimmelman J
BMJ Open; 2020 Feb; 10(2):e034306. PubMed ID: 32071183
[TBL] [Abstract][Full Text] [Related]
20. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
